&m5J|& R? 7 Bao-Aat y+G;@l[r\;j #Ml}Z + g/%$: {RthUE!NQ cLmt#}t,sms# PPI2 zbOXoz3zb _J m,W~@PWT nqAM NDv?CoD$fNDdN?ePUN^ )}2}0 L[T?T$L 4A$@n12Af@2 *2,w20Qx 5Duu@. ,:P OY9;QR9 O] byY 5hg 1t$#V dnd}kw6w O9 FCE8 9d)zY /6a `?1T1|]1f HE XzNP `[3oDi((o.

Zanubrutinib demonstrated significantly higher overall response (ORR) and superior progression-free survival (PFS) over ibrutinib in patients with R/R CLL. This PFS benefit was reported across all major subgroups, including the del(17p)/Cgn2^=cv population. Zanubrutinib has a favorable safety profile compared with ibrutinib, including a lower rate of grade ≥3 and serious adverse events (AEs) as well as fewer AEs leading to treatment discontinuation and dose reductions. Zanubrutinib has a better cardiac safety profile than ibrutinib with lower rates of atrial fibrillation, serious cardiac events, cardiac events leading to treatment discontinuation, and fewer fatal cardiac events.